P-037 - Advanced Pancreatic Cancer Patients Characteristics, Treatment and Outcome Based on Three Age Groups: ≤ 39, 39-74 and ≥ 75, a Report from Single...

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Cancer Aetiology, Epidemiology, Prevention
Pancreatic Cancer
Presenter M. Gilabert
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors M. Gilabert1, R.Y. Soo1, T. Kavan1, A. Mamo1, J. Mc Lean1, P. Viens2, J.L. Raoul3, G. Batist1, P. Kavan4
  • 1McGill University, Montreal/CA
  • 2Paoli-Calmettes Institute, Marseille/FR
  • 3Centre Paoli-Calmettes, Marseille/FR
  • 4Jewish General Hospital, Montreal/CA

Abstract

Introduction

Many factors contribute and determine treatment outcomes of patients with advanced pancreatic cancer (PCa). Recent studies have suggested that age may play a significant role. The purpose of this study was to characterise and evaluate the differences existing between each age group, and understand possible impact of age on treatment efficacy and outcomes.

Methods

Retrospective study was performed on patients diagnosed with locally advanced or metastatic pancreatic adenocarcinoma from Segal Cancer Center, Montreal, Canada, between 2002 and 2015. Age groups were defined as: adolescent and young adult patients (AYA) ≤ 39 years old (yo), ‘middle’ group patients (M) between 40 and 74 yo and geriatric patients (Geri) ≥ 75 yo. Study parameters included patients' demographics, treatments and outcomes. Statistical analyses for overall survival (OS), progression free survival 1 [date from 1st line treatment to progression/death (PFS 1)] and 2 [date from 2nd line treatment to progression/death (PFS2)] were estimated with Kaplan Meyer method.

Results

A total of 74 patients were identified with a median age of 58 years [33-92]. For all three cohorts, median follow-up was 21 months [0.1-195], median OS was 18.4 months, median PFS1 and median PFS2 were 3.1 and 2.2 months, respectively. We identified 10 AYA, 51 M and 14 Geri patients. Main differences on patients' demographics showed male gender predominance (61%) except for M group (female = 53%), primary tumor location to be head of the pancreas (60%) except for Geri group (unknown location in 30% (or not investigated)) and more metastatic disease at the time of diagnosis for AYA patients (90% vs 56% for M group and 61% for Geri). Main systemic treatment choices are presented in Table 1. Survival analyses demonstrated significant differences between 3 groups for Median OS but not for PFS1 and PFS2 (Table 2).

Conclusion

Significant differences between each age group in terms of characteristics, treatment patterns and outcomes were found. Despite the small cohort of AYA patients, our study suggests that they may have more aggressive disease and a worse outcome, despite the tendency of receiving more ‘aggressive’ systemic treatments. Irrespective of the age group, less than 10% received third line of chemotherapy and OS was < 2 years, reiterating poor prognosis of advanced/metastatic PCa. Further clinical and biological research to understand differences in each age group is warranted.

Table: P-037